



Regd. Office:

'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India. Phone: +91-79-2686 8100 (20 Lines)

Fax : +91-79-2686 2368 www.zyduscadila.com CIN:L24230GJ1995PLC025878

December 1, 2017

BSE Limited 1st Floor, P J Towers, Dalal Street, Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Re.: Press Release

Dear Sir / Madam,

We enclose herewith a copy of press release dated December 1, 2017 titled "Zydus receives tentative approval from the USFDA for Pregabalin Capsules".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, CADILA HEALTHCARE LIMITED

UPEN H. SHAH COMPANY SECRETARY

Encl.: As above



Press Release

Press Release

Zydus receives tentative approval from the USFDA for Pregabalin Capsules

, heledae

Ahmedabad, 1 December, 2017

Zydus Pharmaceuticals (USA) Inc., a wholly owned subsidiary of Cadila Healthcare Limited, has received the tentative approval from the USFDA to market Pregabalin Capsules in strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. The drug is used for management of certain kinds of seizures, neuropathic pain (nerve pain) and fibromyalgia. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 175 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
